新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 投资 » True North融资2200万美元开发罕见病药物

True North融资2200万美元开发罕见病药物

来源:生物谷 2014-06-19 10:27

2014年6月19日讯 /生物谷BIOON/ --True North公司CEO Nancy Stagliano最近宣布公司已经获得2200万美元投资用于开发一项早期抗体药物TNT009治疗罕见血液病、肾病以及神经性疾病。TNT009能够有效阻断C1酶,这种酶在免疫反映中扮演重要角色。阻断C1能够阻止患者身体过度免疫从而治疗一些由此引起的疾病。此轮投资的投资方包括Kleiner Perkins Caufield & Byers公司、 MPM Capital公司以及葛兰素史克等大型制药公司的投资部门。利用这笔投资公司希望完成TNT009的临床前研究并顺利进入临床一期研究。(生物谷Bioon.com)

详细英文报道:

Two months removed from a deal that sent her last biotech to Bristol-Myers Squibb ($BMY) for up to $725 million, CEO Nancy Stagliano isn't wasting any time, setting sights on rare diseases with True North Therapeutics, her latest venture, and locking down a $22 million A round to move forward.

Formed as a spinoff of iPierian in September, True North is developing an early-stage antibody with promise in rare hematological, renal and neurological ailments, the company said.

Dubbed TNT009, the biotech's lead candidate works by inhibiting the C1 enzyme, part of the immune system's complement pathway. Doing so brings a halt to many self-attacking antibodies, the company said, preventing downstream disease processes while maintaining necessary immune function.

The $22 million financing comes courtesy of biotech backers Kleiner Perkins Caufield & Byers and MPM Capital, along with the venture arms of drug giants GlaxoSmithKline ($GSK), Biogen Idec ($BIIB) and Baxter ($BAX). With the cash, True North plans to roll TNT009's preclinical success into Phase I, planning to begin a first human trial in early 2015.

That's a quick turnaround from the last days of iPierian. Bristol-Myers' deal--$175 million up front and as much as $550 million in milestones--closed April 29.

"There was really no time to take a breather, because we had to raise our Series A and keep True North going," Stagliano told FierceBiotech. "But those are good problems to have."

With iPierian in the rear view, Stagliano has recruited her former Millennium Pharmaceuticals colleague James Gilbert to serve as chief medical officer and oversee TNT009's clinical entré. Before his stint heading up cardiovascular and inflammation R&D at Millennium, Gilbert worked his way up to cardio and metabolic chief at Boehringer Ingelheim and spent time with Bayer.

Key to True North's fast pace is consistency, Stagliano said. In forming the biotech last year, iPierian bisected its business but kept management intact. Thus, the Bristol-Myers sale didn't disrupt its R&D engine, and True North had little trouble rallying around TNT009 in the immediate aftermath of the iPierian deal.

"At this point, we're a well-oiled machine," Stagliano said. "We're antibody experts. We've vetted the CROs, the contractors we use, the consultants that we use. We're ready to really just execute on this plan."

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库